"The U.S. Food and Drug Administration today approved Tretten, Coagulation Factor XIII A-Subunit (Recombinant), the first recombinant product for use in the routine prevention of bleeding in adults and children who have a rare clotting disorder, k"...
Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight or its components (including traces of hamster proteins).This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 3/25/2014
Additional Novoeight Information
Report Problems to the Food and Drug Administration
Find out what women really need.